nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—ABCB1—hematologic cancer	0.0742	1	CbGaD
Citalopram—CYP1A2—Anagrelide—hematologic cancer	0.0235	0.0425	CbGbCtD
Citalopram—CYP2B6—Thiotepa—hematologic cancer	0.023	0.0417	CbGbCtD
Citalopram—CYP2E1—Thalidomide—hematologic cancer	0.015	0.0272	CbGbCtD
Citalopram—ABCB1—Lenalidomide—hematologic cancer	0.0142	0.0258	CbGbCtD
Citalopram—CYP2B6—Ifosfamide—hematologic cancer	0.0131	0.0236	CbGbCtD
Citalopram—CYP2E1—Dacarbazine—hematologic cancer	0.0129	0.0234	CbGbCtD
Citalopram—CYP2D6—Lomustine—hematologic cancer	0.0125	0.0226	CbGbCtD
Citalopram—CYP1A2—Carmustine—hematologic cancer	0.0123	0.0223	CbGbCtD
Citalopram—CYP2B6—Nilotinib—hematologic cancer	0.0113	0.0205	CbGbCtD
Citalopram—CYP2D6—Idarubicin—hematologic cancer	0.0111	0.0201	CbGbCtD
Citalopram—CYP2C19—Bortezomib—hematologic cancer	0.0108	0.0196	CbGbCtD
Citalopram—CYP1A2—Methoxsalen—hematologic cancer	0.0105	0.019	CbGbCtD
Citalopram—CYP2E1—Mitoxantrone—hematologic cancer	0.01	0.0182	CbGbCtD
Citalopram—CYP1A2—Bortezomib—hematologic cancer	0.00998	0.0181	CbGbCtD
Citalopram—CYP1A2—Daunorubicin—hematologic cancer	0.00954	0.0173	CbGbCtD
Citalopram—CYP2D6—Hydroxyurea—hematologic cancer	0.00945	0.0171	CbGbCtD
Citalopram—CYP2C19—Thalidomide—hematologic cancer	0.00942	0.0171	CbGbCtD
Citalopram—CYP1A2—Alitretinoin—hematologic cancer	0.00935	0.0169	CbGbCtD
Citalopram—CYP2C19—Teniposide—hematologic cancer	0.00899	0.0163	CbGbCtD
Citalopram—CYP1A2—Thalidomide—hematologic cancer	0.00869	0.0157	CbGbCtD
Citalopram—CYP3A4—Bexarotene—hematologic cancer	0.00853	0.0154	CbGbCtD
Citalopram—ABCB1—Daunorubicin—hematologic cancer	0.00835	0.0151	CbGbCtD
Citalopram—CYP2C19—Ifosfamide—hematologic cancer	0.00829	0.015	CbGbCtD
Citalopram—CYP2D6—Bortezomib—hematologic cancer	0.00822	0.0149	CbGbCtD
Citalopram—ABCB1—Alitretinoin—hematologic cancer	0.00818	0.0148	CbGbCtD
Citalopram—CYP3A4—Lomustine—hematologic cancer	0.00793	0.0144	CbGbCtD
Citalopram—CYP3A4—Busulfan—hematologic cancer	0.00793	0.0144	CbGbCtD
Citalopram—CYP2C19—Imatinib—hematologic cancer	0.00792	0.0143	CbGbCtD
Citalopram—CYP2B6—Irinotecan—hematologic cancer	0.00779	0.0141	CbGbCtD
Citalopram—CYP1A2—Dacarbazine—hematologic cancer	0.00748	0.0135	CbGbCtD
Citalopram—CYP1A2—Imatinib—hematologic cancer	0.00731	0.0132	CbGbCtD
Citalopram—CYP3A4—Thiotepa—hematologic cancer	0.00707	0.0128	CbGbCtD
Citalopram—ABCB1—Imatinib—hematologic cancer	0.00639	0.0116	CbGbCtD
Citalopram—CYP2B6—Cisplatin—hematologic cancer	0.00635	0.0115	CbGbCtD
Citalopram—CYP2E1—Etoposide—hematologic cancer	0.00632	0.0114	CbGbCtD
Citalopram—CYP2D6—Imatinib—hematologic cancer	0.00602	0.0109	CbGbCtD
Citalopram—CYP1A2—Dasatinib—hematologic cancer	0.00587	0.0106	CbGbCtD
Citalopram—ABCB1—Nilotinib—hematologic cancer	0.00581	0.0105	CbGbCtD
Citalopram—ABCB1—Vinorelbine—hematologic cancer	0.00576	0.0104	CbGbCtD
Citalopram—CYP3A4—Methoxsalen—hematologic cancer	0.0055	0.00995	CbGbCtD
Citalopram—CYP2D6—Nilotinib—hematologic cancer	0.00547	0.00991	CbGbCtD
Citalopram—CYP2D6—Vinorelbine—hematologic cancer	0.00543	0.00983	CbGbCtD
Citalopram—CYP3A4—Bortezomib—hematologic cancer	0.00523	0.00946	CbGbCtD
Citalopram—CYP2C19—Prednisone—hematologic cancer	0.00522	0.00945	CbGbCtD
Citalopram—CYP2E1—Dexamethasone—hematologic cancer	0.0052	0.00941	CbGbCtD
Citalopram—ABCB1—Dasatinib—hematologic cancer	0.00513	0.0093	CbGbCtD
Citalopram—CYP2B6—Dexamethasone—hematologic cancer	0.00513	0.00929	CbGbCtD
Citalopram—ABCB1—Mitoxantrone—hematologic cancer	0.00507	0.00918	CbGbCtD
Citalopram—CYP3A4—Daunorubicin—hematologic cancer	0.005	0.00905	CbGbCtD
Citalopram—ABCB1—Betamethasone—hematologic cancer	0.00452	0.00818	CbGbCtD
Citalopram—ABCB1—Gemcitabine—hematologic cancer	0.00448	0.00811	CbGbCtD
Citalopram—ABCB1—Prednisolone—hematologic cancer	0.00446	0.00807	CbGbCtD
Citalopram—CYP3A4—Cytarabine—hematologic cancer	0.00441	0.00799	CbGbCtD
Citalopram—CYP3A4—Teniposide—hematologic cancer	0.00434	0.00787	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—hematologic cancer	0.00425	0.0077	CbGbCtD
Citalopram—ABCB1—Prednisone—hematologic cancer	0.00421	0.00763	CbGbCtD
Citalopram—CYP3A4—Ifosfamide—hematologic cancer	0.00401	0.00726	CbGbCtD
Citalopram—ABCB1—Irinotecan—hematologic cancer	0.00399	0.00723	CbGbCtD
Citalopram—CYP3A4—Imatinib—hematologic cancer	0.00383	0.00693	CbGbCtD
Citalopram—CYP1A2—Etoposide—hematologic cancer	0.00366	0.00662	CbGbCtD
Citalopram—CYP3A4—Ruxolitinib—hematologic cancer	0.00361	0.00653	CbGbCtD
Citalopram—ABCB1—Vinblastine—hematologic cancer	0.00355	0.00643	CbGbCtD
Citalopram—ABCB1—Vincristine—hematologic cancer	0.00349	0.00632	CbGbCtD
Citalopram—CYP3A4—Nilotinib—hematologic cancer	0.00348	0.0063	CbGbCtD
Citalopram—CYP3A4—Vinorelbine—hematologic cancer	0.00345	0.00625	CbGbCtD
Citalopram—CYP2D6—Vinblastine—hematologic cancer	0.00335	0.00606	CbGbCtD
Citalopram—CYP2C19—Dexamethasone—hematologic cancer	0.00326	0.0059	CbGbCtD
Citalopram—ABCB1—Cisplatin—hematologic cancer	0.00326	0.00589	CbGbCtD
Citalopram—ABCB1—Etoposide—hematologic cancer	0.0032	0.00579	CbGbCtD
Citalopram—CYP3A4—Triamcinolone—hematologic cancer	0.00316	0.00572	CbGbCtD
Citalopram—CYP3A4—Dasatinib—hematologic cancer	0.00308	0.00557	CbGbCtD
Citalopram—CYP3A4—Mitoxantrone—hematologic cancer	0.00304	0.0055	CbGbCtD
Citalopram—CYP3A4—Betamethasone—hematologic cancer	0.00271	0.0049	CbGbCtD
Citalopram—CYP3A4—Prednisolone—hematologic cancer	0.00267	0.00484	CbGbCtD
Citalopram—ABCB1—Dexamethasone—hematologic cancer	0.00263	0.00476	CbGbCtD
Citalopram—CYP3A4—Prednisone—hematologic cancer	0.00252	0.00457	CbGbCtD
Citalopram—CYP2D6—Dexamethasone—hematologic cancer	0.00248	0.00449	CbGbCtD
Citalopram—CYP3A4—Irinotecan—hematologic cancer	0.00239	0.00433	CbGbCtD
Citalopram—ABCB1—Doxorubicin—hematologic cancer	0.00218	0.00395	CbGbCtD
Citalopram—CYP3A4—Vinblastine—hematologic cancer	0.00213	0.00385	CbGbCtD
Citalopram—ABCB1—Methotrexate—hematologic cancer	0.00211	0.00383	CbGbCtD
Citalopram—CYP3A4—Vincristine—hematologic cancer	0.00209	0.00379	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—hematologic cancer	0.00206	0.00372	CbGbCtD
Citalopram—CYP3A4—Etoposide—hematologic cancer	0.00192	0.00347	CbGbCtD
Citalopram—CYP3A4—Dexamethasone—hematologic cancer	0.00158	0.00285	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—hematologic cancer	0.00131	0.00237	CbGbCtD
Citalopram—SLC6A3—hematopoietic system—hematologic cancer	0.000771	0.0532	CbGeAlD
Citalopram—SLC6A4—hematopoietic system—hematologic cancer	0.000707	0.0488	CbGeAlD
Citalopram—CYP2C19—hematopoietic system—hematologic cancer	0.000586	0.0404	CbGeAlD
Citalopram—ADRA1A—hematopoietic system—hematologic cancer	0.000578	0.0399	CbGeAlD
Citalopram—CYP1A2—hematopoietic system—hematologic cancer	0.000478	0.033	CbGeAlD
Citalopram—SLC6A2—gonad—hematologic cancer	0.000473	0.0327	CbGeAlD
Citalopram—SLC6A4—blood—hematologic cancer	0.000468	0.0323	CbGeAlD
Citalopram—CYP2B6—hematopoietic system—hematologic cancer	0.000458	0.0317	CbGeAlD
Citalopram—SLC6A3—lung—hematologic cancer	0.000448	0.0309	CbGeAlD
Citalopram—HRH1—hematopoietic system—hematologic cancer	0.000448	0.0309	CbGeAlD
Citalopram—CYP2E1—hematopoietic system—hematologic cancer	0.00043	0.0297	CbGeAlD
Citalopram—SLC6A3—testis—hematologic cancer	0.000423	0.0292	CbGeAlD
Citalopram—SLC6A4—lung—hematologic cancer	0.00041	0.0283	CbGeAlD
Citalopram—CHRM1—lung—hematologic cancer	0.000409	0.0282	CbGeAlD
Citalopram—CYP2C19—blood—hematologic cancer	0.000388	0.0268	CbGeAlD
Citalopram—ADRA1A—blood—hematologic cancer	0.000383	0.0265	CbGeAlD
Citalopram—SLC6A2—lung—hematologic cancer	0.000361	0.025	CbGeAlD
Citalopram—CYP2B6—gonad—hematologic cancer	0.000349	0.0241	CbGeAlD
Citalopram—CYP3A4—hematopoietic system—hematologic cancer	0.000346	0.0239	CbGeAlD
Citalopram—SLC6A2—testis—hematologic cancer	0.000341	0.0235	CbGeAlD
Citalopram—CYP2D6—hematopoietic system—hematologic cancer	0.000341	0.0235	CbGeAlD
Citalopram—CYP1A2—blood—hematologic cancer	0.000317	0.0219	CbGeAlD
Citalopram—CYP2B6—blood—hematologic cancer	0.000304	0.021	CbGeAlD
Citalopram—CYP2E1—blood—hematologic cancer	0.000285	0.0197	CbGeAlD
Citalopram—CYP1A2—lung—hematologic cancer	0.000278	0.0192	CbGeAlD
Citalopram—CYP2B6—lung—hematologic cancer	0.000266	0.0184	CbGeAlD
Citalopram—HRH1—lung—hematologic cancer	0.00026	0.018	CbGeAlD
Citalopram—CYP2B6—testis—hematologic cancer	0.000251	0.0173	CbGeAlD
Citalopram—CYP2E1—lung—hematologic cancer	0.00025	0.0173	CbGeAlD
Citalopram—SLC6A2—lymph node—hematologic cancer	0.000247	0.0171	CbGeAlD
Citalopram—HRH1—testis—hematologic cancer	0.000245	0.0169	CbGeAlD
Citalopram—ABCB1—hematopoietic system—hematologic cancer	0.000245	0.0169	CbGeAlD
Citalopram—CYP2E1—testis—hematologic cancer	0.000236	0.0163	CbGeAlD
Citalopram—CYP3A4—blood—hematologic cancer	0.000229	0.0158	CbGeAlD
Citalopram—CYP2D6—blood—hematologic cancer	0.000226	0.0156	CbGeAlD
Citalopram—CYP2D6—testis—hematologic cancer	0.000187	0.0129	CbGeAlD
Citalopram—ABCB1—gonad—hematologic cancer	0.000186	0.0129	CbGeAlD
Citalopram—HRH1—lymph node—hematologic cancer	0.000178	0.0123	CbGeAlD
Citalopram—ABCB1—blood—hematologic cancer	0.000162	0.0112	CbGeAlD
Citalopram—ABCB1—bone marrow—hematologic cancer	0.000157	0.0108	CbGeAlD
Citalopram—ABCB1—lung—hematologic cancer	0.000142	0.00983	CbGeAlD
Citalopram—ABCB1—testis—hematologic cancer	0.000134	0.00927	CbGeAlD
Citalopram—ABCB1—lymph node—hematologic cancer	9.73e-05	0.00672	CbGeAlD
Citalopram—Flatulence—Epirubicin—hematologic cancer	9.16e-06	3.15e-05	CcSEcCtD
Citalopram—Tension—Epirubicin—hematologic cancer	9.13e-06	3.13e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Dexamethasone—hematologic cancer	9.11e-06	3.13e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Betamethasone—hematologic cancer	9.11e-06	3.13e-05	CcSEcCtD
Citalopram—Dysgeusia—Epirubicin—hematologic cancer	9.11e-06	3.13e-05	CcSEcCtD
Citalopram—Hypersensitivity—Triamcinolone—hematologic cancer	9.05e-06	3.11e-05	CcSEcCtD
Citalopram—Nervousness—Epirubicin—hematologic cancer	9.03e-06	3.1e-05	CcSEcCtD
Citalopram—Back pain—Epirubicin—hematologic cancer	9e-06	3.09e-05	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—hematologic cancer	8.97e-06	3.08e-05	CcSEcCtD
Citalopram—Malaise—Methotrexate—hematologic cancer	8.96e-06	3.08e-05	CcSEcCtD
Citalopram—Dizziness—Etoposide—hematologic cancer	8.95e-06	3.07e-05	CcSEcCtD
Citalopram—Muscle spasms—Epirubicin—hematologic cancer	8.94e-06	3.07e-05	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—hematologic cancer	8.93e-06	3.07e-05	CcSEcCtD
Citalopram—Vertigo—Methotrexate—hematologic cancer	8.93e-06	3.07e-05	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—hematologic cancer	8.91e-06	3.06e-05	CcSEcCtD
Citalopram—Leukopenia—Methotrexate—hematologic cancer	8.9e-06	3.05e-05	CcSEcCtD
Citalopram—Chills—Doxorubicin—hematologic cancer	8.87e-06	3.04e-05	CcSEcCtD
Citalopram—Urticaria—Dexamethasone—hematologic cancer	8.85e-06	3.04e-05	CcSEcCtD
Citalopram—Urticaria—Betamethasone—hematologic cancer	8.85e-06	3.04e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Prednisone—hematologic cancer	8.84e-06	3.04e-05	CcSEcCtD
Citalopram—Dizziness—Prednisolone—hematologic cancer	8.83e-06	3.03e-05	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—hematologic cancer	8.83e-06	3.03e-05	CcSEcCtD
Citalopram—Asthenia—Triamcinolone—hematologic cancer	8.81e-06	3.03e-05	CcSEcCtD
Citalopram—Body temperature increased—Dexamethasone—hematologic cancer	8.81e-06	3.02e-05	CcSEcCtD
Citalopram—Abdominal pain—Dexamethasone—hematologic cancer	8.81e-06	3.02e-05	CcSEcCtD
Citalopram—Body temperature increased—Betamethasone—hematologic cancer	8.81e-06	3.02e-05	CcSEcCtD
Citalopram—Abdominal pain—Betamethasone—hematologic cancer	8.81e-06	3.02e-05	CcSEcCtD
Citalopram—Nausea—Cisplatin—hematologic cancer	8.78e-06	3.01e-05	CcSEcCtD
Citalopram—Insomnia—Prednisone—hematologic cancer	8.78e-06	3.01e-05	CcSEcCtD
Citalopram—Vision blurred—Epirubicin—hematologic cancer	8.77e-06	3.01e-05	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—hematologic cancer	8.74e-06	3e-05	CcSEcCtD
Citalopram—Paraesthesia—Prednisone—hematologic cancer	8.71e-06	2.99e-05	CcSEcCtD
Citalopram—Pruritus—Triamcinolone—hematologic cancer	8.69e-06	2.98e-05	CcSEcCtD
Citalopram—Cough—Methotrexate—hematologic cancer	8.67e-06	2.98e-05	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—hematologic cancer	8.66e-06	2.97e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Epirubicin—hematologic cancer	8.63e-06	2.96e-05	CcSEcCtD
Citalopram—Convulsion—Methotrexate—hematologic cancer	8.61e-06	2.96e-05	CcSEcCtD
Citalopram—Vomiting—Etoposide—hematologic cancer	8.61e-06	2.96e-05	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—hematologic cancer	8.61e-06	2.95e-05	CcSEcCtD
Citalopram—Erythema—Doxorubicin—hematologic cancer	8.61e-06	2.95e-05	CcSEcCtD
Citalopram—Anaemia—Epirubicin—hematologic cancer	8.6e-06	2.95e-05	CcSEcCtD
Citalopram—Agitation—Epirubicin—hematologic cancer	8.55e-06	2.93e-05	CcSEcCtD
Citalopram—Dyspepsia—Prednisone—hematologic cancer	8.54e-06	2.93e-05	CcSEcCtD
Citalopram—Rash—Etoposide—hematologic cancer	8.54e-06	2.93e-05	CcSEcCtD
Citalopram—Dermatitis—Etoposide—hematologic cancer	8.53e-06	2.93e-05	CcSEcCtD
Citalopram—Headache—Etoposide—hematologic cancer	8.48e-06	2.91e-05	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—hematologic cancer	8.48e-06	2.91e-05	CcSEcCtD
Citalopram—Chest pain—Methotrexate—hematologic cancer	8.46e-06	2.9e-05	CcSEcCtD
Citalopram—Myalgia—Methotrexate—hematologic cancer	8.46e-06	2.9e-05	CcSEcCtD
Citalopram—Arthralgia—Methotrexate—hematologic cancer	8.46e-06	2.9e-05	CcSEcCtD
Citalopram—Tension—Doxorubicin—hematologic cancer	8.44e-06	2.9e-05	CcSEcCtD
Citalopram—Decreased appetite—Prednisone—hematologic cancer	8.44e-06	2.9e-05	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—hematologic cancer	8.43e-06	2.89e-05	CcSEcCtD
Citalopram—Rash—Prednisolone—hematologic cancer	8.42e-06	2.89e-05	CcSEcCtD
Citalopram—Dermatitis—Prednisolone—hematologic cancer	8.41e-06	2.89e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	8.4e-06	2.88e-05	CcSEcCtD
Citalopram—Malaise—Epirubicin—hematologic cancer	8.39e-06	2.88e-05	CcSEcCtD
Citalopram—Fatigue—Prednisone—hematologic cancer	8.37e-06	2.87e-05	CcSEcCtD
Citalopram—Headache—Prednisolone—hematologic cancer	8.37e-06	2.87e-05	CcSEcCtD
Citalopram—Discomfort—Methotrexate—hematologic cancer	8.36e-06	2.87e-05	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—hematologic cancer	8.36e-06	2.87e-05	CcSEcCtD
Citalopram—Vertigo—Epirubicin—hematologic cancer	8.36e-06	2.87e-05	CcSEcCtD
Citalopram—Syncope—Epirubicin—hematologic cancer	8.34e-06	2.86e-05	CcSEcCtD
Citalopram—Leukopenia—Epirubicin—hematologic cancer	8.33e-06	2.86e-05	CcSEcCtD
Citalopram—Back pain—Doxorubicin—hematologic cancer	8.32e-06	2.86e-05	CcSEcCtD
Citalopram—Constipation—Prednisone—hematologic cancer	8.3e-06	2.85e-05	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—hematologic cancer	8.27e-06	2.84e-05	CcSEcCtD
Citalopram—Palpitations—Epirubicin—hematologic cancer	8.22e-06	2.82e-05	CcSEcCtD
Citalopram—Confusional state—Methotrexate—hematologic cancer	8.18e-06	2.81e-05	CcSEcCtD
Citalopram—Loss of consciousness—Epirubicin—hematologic cancer	8.17e-06	2.81e-05	CcSEcCtD
Citalopram—Dizziness—Triamcinolone—hematologic cancer	8.12e-06	2.79e-05	CcSEcCtD
Citalopram—Cough—Epirubicin—hematologic cancer	8.12e-06	2.79e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Methotrexate—hematologic cancer	8.11e-06	2.78e-05	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—hematologic cancer	8.11e-06	2.78e-05	CcSEcCtD
Citalopram—Convulsion—Epirubicin—hematologic cancer	8.06e-06	2.77e-05	CcSEcCtD
Citalopram—Infection—Methotrexate—hematologic cancer	8.06e-06	2.77e-05	CcSEcCtD
Citalopram—Nausea—Etoposide—hematologic cancer	8.04e-06	2.76e-05	CcSEcCtD
Citalopram—Hypertension—Epirubicin—hematologic cancer	8.03e-06	2.76e-05	CcSEcCtD
Citalopram—Feeling abnormal—Prednisone—hematologic cancer	8e-06	2.75e-05	CcSEcCtD
Citalopram—Asthenia—Betamethasone—hematologic cancer	8e-06	2.74e-05	CcSEcCtD
Citalopram—Asthenia—Dexamethasone—hematologic cancer	8e-06	2.74e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—hematologic cancer	7.98e-06	2.74e-05	CcSEcCtD
Citalopram—Nervous system disorder—Methotrexate—hematologic cancer	7.95e-06	2.73e-05	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—hematologic cancer	7.95e-06	2.73e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Methotrexate—hematologic cancer	7.94e-06	2.73e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Prednisone—hematologic cancer	7.94e-06	2.72e-05	CcSEcCtD
Citalopram—Nausea—Prednisolone—hematologic cancer	7.93e-06	2.72e-05	CcSEcCtD
Citalopram—Myalgia—Epirubicin—hematologic cancer	7.92e-06	2.72e-05	CcSEcCtD
Citalopram—Chest pain—Epirubicin—hematologic cancer	7.92e-06	2.72e-05	CcSEcCtD
Citalopram—Arthralgia—Epirubicin—hematologic cancer	7.92e-06	2.72e-05	CcSEcCtD
Citalopram—Agitation—Doxorubicin—hematologic cancer	7.91e-06	2.71e-05	CcSEcCtD
Citalopram—Anxiety—Epirubicin—hematologic cancer	7.89e-06	2.71e-05	CcSEcCtD
Citalopram—Pruritus—Dexamethasone—hematologic cancer	7.88e-06	2.71e-05	CcSEcCtD
Citalopram—Pruritus—Betamethasone—hematologic cancer	7.88e-06	2.71e-05	CcSEcCtD
Citalopram—Skin disorder—Methotrexate—hematologic cancer	7.88e-06	2.7e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	7.86e-06	2.7e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Methotrexate—hematologic cancer	7.84e-06	2.69e-05	CcSEcCtD
Citalopram—Discomfort—Epirubicin—hematologic cancer	7.82e-06	2.69e-05	CcSEcCtD
Citalopram—Vomiting—Triamcinolone—hematologic cancer	7.81e-06	2.68e-05	CcSEcCtD
Citalopram—Malaise—Doxorubicin—hematologic cancer	7.76e-06	2.66e-05	CcSEcCtD
Citalopram—Rash—Triamcinolone—hematologic cancer	7.74e-06	2.66e-05	CcSEcCtD
Citalopram—Dry mouth—Epirubicin—hematologic cancer	7.74e-06	2.66e-05	CcSEcCtD
Citalopram—Dermatitis—Triamcinolone—hematologic cancer	7.74e-06	2.66e-05	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—hematologic cancer	7.73e-06	2.65e-05	CcSEcCtD
Citalopram—Anorexia—Methotrexate—hematologic cancer	7.73e-06	2.65e-05	CcSEcCtD
Citalopram—Syncope—Doxorubicin—hematologic cancer	7.72e-06	2.65e-05	CcSEcCtD
Citalopram—Urticaria—Prednisone—hematologic cancer	7.71e-06	2.65e-05	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—hematologic cancer	7.7e-06	2.64e-05	CcSEcCtD
Citalopram—Headache—Triamcinolone—hematologic cancer	7.69e-06	2.64e-05	CcSEcCtD
Citalopram—Abdominal pain—Prednisone—hematologic cancer	7.67e-06	2.63e-05	CcSEcCtD
Citalopram—Body temperature increased—Prednisone—hematologic cancer	7.67e-06	2.63e-05	CcSEcCtD
Citalopram—Confusional state—Epirubicin—hematologic cancer	7.65e-06	2.63e-05	CcSEcCtD
Citalopram—Diarrhoea—Betamethasone—hematologic cancer	7.62e-06	2.62e-05	CcSEcCtD
Citalopram—Diarrhoea—Dexamethasone—hematologic cancer	7.62e-06	2.62e-05	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—hematologic cancer	7.6e-06	2.61e-05	CcSEcCtD
Citalopram—Oedema—Epirubicin—hematologic cancer	7.59e-06	2.61e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Epirubicin—hematologic cancer	7.59e-06	2.61e-05	CcSEcCtD
Citalopram—Hypotension—Methotrexate—hematologic cancer	7.58e-06	2.6e-05	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—hematologic cancer	7.56e-06	2.6e-05	CcSEcCtD
Citalopram—Infection—Epirubicin—hematologic cancer	7.54e-06	2.59e-05	CcSEcCtD
Citalopram—Cough—Doxorubicin—hematologic cancer	7.51e-06	2.58e-05	CcSEcCtD
Citalopram—Shock—Epirubicin—hematologic cancer	7.47e-06	2.56e-05	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—hematologic cancer	7.46e-06	2.56e-05	CcSEcCtD
Citalopram—Nervous system disorder—Epirubicin—hematologic cancer	7.44e-06	2.56e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Epirubicin—hematologic cancer	7.43e-06	2.55e-05	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—hematologic cancer	7.43e-06	2.55e-05	CcSEcCtD
Citalopram—Tachycardia—Epirubicin—hematologic cancer	7.41e-06	2.54e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Methotrexate—hematologic cancer	7.39e-06	2.54e-05	CcSEcCtD
Citalopram—Skin disorder—Epirubicin—hematologic cancer	7.37e-06	2.53e-05	CcSEcCtD
Citalopram—Dizziness—Betamethasone—hematologic cancer	7.37e-06	2.53e-05	CcSEcCtD
Citalopram—Dizziness—Dexamethasone—hematologic cancer	7.37e-06	2.53e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Epirubicin—hematologic cancer	7.34e-06	2.52e-05	CcSEcCtD
Citalopram—Insomnia—Methotrexate—hematologic cancer	7.34e-06	2.52e-05	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—hematologic cancer	7.33e-06	2.52e-05	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—hematologic cancer	7.33e-06	2.52e-05	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—hematologic cancer	7.33e-06	2.52e-05	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—hematologic cancer	7.3e-06	2.51e-05	CcSEcCtD
Citalopram—Nausea—Triamcinolone—hematologic cancer	7.3e-06	2.5e-05	CcSEcCtD
Citalopram—Paraesthesia—Methotrexate—hematologic cancer	7.28e-06	2.5e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	7.28e-06	2.5e-05	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—hematologic cancer	7.24e-06	2.48e-05	CcSEcCtD
Citalopram—Anorexia—Epirubicin—hematologic cancer	7.24e-06	2.48e-05	CcSEcCtD
Citalopram—Dyspnoea—Methotrexate—hematologic cancer	7.23e-06	2.48e-05	CcSEcCtD
Citalopram—Somnolence—Methotrexate—hematologic cancer	7.21e-06	2.48e-05	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—hematologic cancer	7.17e-06	2.46e-05	CcSEcCtD
Citalopram—Hypersensitivity—Prednisone—hematologic cancer	7.15e-06	2.45e-05	CcSEcCtD
Citalopram—Dyspepsia—Methotrexate—hematologic cancer	7.14e-06	2.45e-05	CcSEcCtD
Citalopram—Hypotension—Epirubicin—hematologic cancer	7.09e-06	2.43e-05	CcSEcCtD
Citalopram—Vomiting—Betamethasone—hematologic cancer	7.09e-06	2.43e-05	CcSEcCtD
Citalopram—Vomiting—Dexamethasone—hematologic cancer	7.09e-06	2.43e-05	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—hematologic cancer	7.08e-06	2.43e-05	CcSEcCtD
Citalopram—Decreased appetite—Methotrexate—hematologic cancer	7.05e-06	2.42e-05	CcSEcCtD
Citalopram—Rash—Dexamethasone—hematologic cancer	7.03e-06	2.41e-05	CcSEcCtD
Citalopram—Rash—Betamethasone—hematologic cancer	7.03e-06	2.41e-05	CcSEcCtD
Citalopram—Oedema—Doxorubicin—hematologic cancer	7.02e-06	2.41e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—hematologic cancer	7.02e-06	2.41e-05	CcSEcCtD
Citalopram—Dermatitis—Betamethasone—hematologic cancer	7.02e-06	2.41e-05	CcSEcCtD
Citalopram—Dermatitis—Dexamethasone—hematologic cancer	7.02e-06	2.41e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Methotrexate—hematologic cancer	7e-06	2.4e-05	CcSEcCtD
Citalopram—Fatigue—Methotrexate—hematologic cancer	6.99e-06	2.4e-05	CcSEcCtD
Citalopram—Headache—Betamethasone—hematologic cancer	6.98e-06	2.4e-05	CcSEcCtD
Citalopram—Headache—Dexamethasone—hematologic cancer	6.98e-06	2.4e-05	CcSEcCtD
Citalopram—Infection—Doxorubicin—hematologic cancer	6.98e-06	2.4e-05	CcSEcCtD
Citalopram—Asthenia—Prednisone—hematologic cancer	6.96e-06	2.39e-05	CcSEcCtD
Citalopram—Pain—Methotrexate—hematologic cancer	6.94e-06	2.38e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.92e-06	2.37e-05	CcSEcCtD
Citalopram—Shock—Doxorubicin—hematologic cancer	6.91e-06	2.37e-05	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—hematologic cancer	6.89e-06	2.36e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—hematologic cancer	6.88e-06	2.36e-05	CcSEcCtD
Citalopram—Pruritus—Prednisone—hematologic cancer	6.87e-06	2.36e-05	CcSEcCtD
Citalopram—Insomnia—Epirubicin—hematologic cancer	6.87e-06	2.36e-05	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—hematologic cancer	6.85e-06	2.35e-05	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—hematologic cancer	6.82e-06	2.34e-05	CcSEcCtD
Citalopram—Paraesthesia—Epirubicin—hematologic cancer	6.82e-06	2.34e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—hematologic cancer	6.79e-06	2.33e-05	CcSEcCtD
Citalopram—Dyspnoea—Epirubicin—hematologic cancer	6.77e-06	2.32e-05	CcSEcCtD
Citalopram—Somnolence—Epirubicin—hematologic cancer	6.75e-06	2.32e-05	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—hematologic cancer	6.69e-06	2.3e-05	CcSEcCtD
Citalopram—Feeling abnormal—Methotrexate—hematologic cancer	6.68e-06	2.29e-05	CcSEcCtD
Citalopram—Dyspepsia—Epirubicin—hematologic cancer	6.68e-06	2.29e-05	CcSEcCtD
Citalopram—Diarrhoea—Prednisone—hematologic cancer	6.64e-06	2.28e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Methotrexate—hematologic cancer	6.63e-06	2.28e-05	CcSEcCtD
Citalopram—Nausea—Dexamethasone—hematologic cancer	6.62e-06	2.27e-05	CcSEcCtD
Citalopram—Nausea—Betamethasone—hematologic cancer	6.62e-06	2.27e-05	CcSEcCtD
Citalopram—Decreased appetite—Epirubicin—hematologic cancer	6.6e-06	2.27e-05	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—hematologic cancer	6.56e-06	2.25e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.55e-06	2.25e-05	CcSEcCtD
Citalopram—Fatigue—Epirubicin—hematologic cancer	6.54e-06	2.25e-05	CcSEcCtD
Citalopram—Constipation—Epirubicin—hematologic cancer	6.49e-06	2.23e-05	CcSEcCtD
Citalopram—Pain—Epirubicin—hematologic cancer	6.49e-06	2.23e-05	CcSEcCtD
Citalopram—Urticaria—Methotrexate—hematologic cancer	6.44e-06	2.21e-05	CcSEcCtD
Citalopram—Dizziness—Prednisone—hematologic cancer	6.42e-06	2.2e-05	CcSEcCtD
Citalopram—Abdominal pain—Methotrexate—hematologic cancer	6.41e-06	2.2e-05	CcSEcCtD
Citalopram—Body temperature increased—Methotrexate—hematologic cancer	6.41e-06	2.2e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	6.4e-06	2.2e-05	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—hematologic cancer	6.35e-06	2.18e-05	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—hematologic cancer	6.31e-06	2.16e-05	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—hematologic cancer	6.26e-06	2.15e-05	CcSEcCtD
Citalopram—Feeling abnormal—Epirubicin—hematologic cancer	6.25e-06	2.15e-05	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—hematologic cancer	6.24e-06	2.14e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Epirubicin—hematologic cancer	6.21e-06	2.13e-05	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—hematologic cancer	6.18e-06	2.12e-05	CcSEcCtD
Citalopram—Vomiting—Prednisone—hematologic cancer	6.17e-06	2.12e-05	CcSEcCtD
Citalopram—Rash—Prednisone—hematologic cancer	6.12e-06	2.1e-05	CcSEcCtD
Citalopram—Dermatitis—Prednisone—hematologic cancer	6.11e-06	2.1e-05	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—hematologic cancer	6.11e-06	2.1e-05	CcSEcCtD
Citalopram—Headache—Prednisone—hematologic cancer	6.08e-06	2.09e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.06e-06	2.08e-05	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—hematologic cancer	6.06e-06	2.08e-05	CcSEcCtD
Citalopram—Urticaria—Epirubicin—hematologic cancer	6.03e-06	2.07e-05	CcSEcCtD
Citalopram—Pain—Doxorubicin—hematologic cancer	6.01e-06	2.06e-05	CcSEcCtD
Citalopram—Constipation—Doxorubicin—hematologic cancer	6.01e-06	2.06e-05	CcSEcCtD
Citalopram—Abdominal pain—Epirubicin—hematologic cancer	6e-06	2.06e-05	CcSEcCtD
Citalopram—Body temperature increased—Epirubicin—hematologic cancer	6e-06	2.06e-05	CcSEcCtD
Citalopram—Hypersensitivity—Methotrexate—hematologic cancer	5.98e-06	2.05e-05	CcSEcCtD
Citalopram—Asthenia—Methotrexate—hematologic cancer	5.82e-06	2e-05	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—hematologic cancer	5.79e-06	1.99e-05	CcSEcCtD
Citalopram—Nausea—Prednisone—hematologic cancer	5.76e-06	1.98e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.74e-06	1.97e-05	CcSEcCtD
Citalopram—Pruritus—Methotrexate—hematologic cancer	5.74e-06	1.97e-05	CcSEcCtD
Citalopram—Hypersensitivity—Epirubicin—hematologic cancer	5.59e-06	1.92e-05	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—hematologic cancer	5.58e-06	1.92e-05	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—hematologic cancer	5.55e-06	1.91e-05	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—hematologic cancer	5.55e-06	1.91e-05	CcSEcCtD
Citalopram—Diarrhoea—Methotrexate—hematologic cancer	5.55e-06	1.91e-05	CcSEcCtD
Citalopram—Asthenia—Epirubicin—hematologic cancer	5.45e-06	1.87e-05	CcSEcCtD
Citalopram—Pruritus—Epirubicin—hematologic cancer	5.37e-06	1.84e-05	CcSEcCtD
Citalopram—Dizziness—Methotrexate—hematologic cancer	5.36e-06	1.84e-05	CcSEcCtD
Citalopram—Diarrhoea—Epirubicin—hematologic cancer	5.19e-06	1.78e-05	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—hematologic cancer	5.17e-06	1.78e-05	CcSEcCtD
Citalopram—Vomiting—Methotrexate—hematologic cancer	5.16e-06	1.77e-05	CcSEcCtD
Citalopram—Rash—Methotrexate—hematologic cancer	5.11e-06	1.76e-05	CcSEcCtD
Citalopram—Dermatitis—Methotrexate—hematologic cancer	5.11e-06	1.75e-05	CcSEcCtD
Citalopram—Headache—Methotrexate—hematologic cancer	5.08e-06	1.74e-05	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—hematologic cancer	5.04e-06	1.73e-05	CcSEcCtD
Citalopram—Dizziness—Epirubicin—hematologic cancer	5.02e-06	1.72e-05	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—hematologic cancer	4.97e-06	1.71e-05	CcSEcCtD
Citalopram—Vomiting—Epirubicin—hematologic cancer	4.83e-06	1.66e-05	CcSEcCtD
Citalopram—Nausea—Methotrexate—hematologic cancer	4.82e-06	1.65e-05	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—hematologic cancer	4.81e-06	1.65e-05	CcSEcCtD
Citalopram—Rash—Epirubicin—hematologic cancer	4.79e-06	1.64e-05	CcSEcCtD
Citalopram—Dermatitis—Epirubicin—hematologic cancer	4.78e-06	1.64e-05	CcSEcCtD
Citalopram—Headache—Epirubicin—hematologic cancer	4.76e-06	1.63e-05	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—hematologic cancer	4.64e-06	1.59e-05	CcSEcCtD
Citalopram—Nausea—Epirubicin—hematologic cancer	4.51e-06	1.55e-05	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—hematologic cancer	4.47e-06	1.53e-05	CcSEcCtD
Citalopram—Rash—Doxorubicin—hematologic cancer	4.43e-06	1.52e-05	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—hematologic cancer	4.42e-06	1.52e-05	CcSEcCtD
Citalopram—Headache—Doxorubicin—hematologic cancer	4.4e-06	1.51e-05	CcSEcCtD
Citalopram—Nausea—Doxorubicin—hematologic cancer	4.17e-06	1.43e-05	CcSEcCtD
Citalopram—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.85e-06	4.22e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.85e-06	4.22e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	2.85e-06	4.21e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CREB1—hematologic cancer	2.84e-06	4.19e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CREB1—hematologic cancer	2.83e-06	4.18e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CREBBP—hematologic cancer	2.83e-06	4.18e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—BRAF—hematologic cancer	2.8e-06	4.14e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK3—hematologic cancer	2.8e-06	4.14e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—BRAF—hematologic cancer	2.79e-06	4.13e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CREB1—hematologic cancer	2.78e-06	4.12e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCL2—hematologic cancer	2.78e-06	4.1e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JAK2—hematologic cancer	2.78e-06	4.1e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6R—hematologic cancer	2.77e-06	4.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCL2—hematologic cancer	2.77e-06	4.09e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CREBBP—hematologic cancer	2.77e-06	4.09e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CREBBP—hematologic cancer	2.76e-06	4.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6R—hematologic cancer	2.76e-06	4.08e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	2.76e-06	4.07e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	2.75e-06	4.06e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—MTHFR—hematologic cancer	2.74e-06	4.05e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	2.72e-06	4.03e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—hematologic cancer	2.72e-06	4.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	2.72e-06	4.02e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	2.71e-06	4.01e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MDM2—hematologic cancer	2.71e-06	4.01e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CD—hematologic cancer	2.68e-06	3.96e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—MTHFR—hematologic cancer	2.68e-06	3.95e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	2.67e-06	3.94e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ALB—hematologic cancer	2.64e-06	3.91e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAP2K1—hematologic cancer	2.64e-06	3.9e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MTOR—hematologic cancer	2.64e-06	3.9e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CB—hematologic cancer	2.64e-06	3.9e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—hematologic cancer	2.63e-06	3.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	2.63e-06	3.89e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CD—hematologic cancer	2.62e-06	3.88e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CD—hematologic cancer	2.62e-06	3.87e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	2.61e-06	3.86e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.6e-06	3.84e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ALB—hematologic cancer	2.59e-06	3.83e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	2.59e-06	3.83e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	2.59e-06	3.83e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	2.57e-06	3.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—hematologic cancer	2.57e-06	3.79e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	2.56e-06	3.78e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.55e-06	3.77e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	2.54e-06	3.76e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3R1—hematologic cancer	2.53e-06	3.74e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.52e-06	3.73e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	2.52e-06	3.72e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—hematologic cancer	2.52e-06	3.72e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—FGF2—hematologic cancer	2.51e-06	3.71e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—FGF2—hematologic cancer	2.5e-06	3.7e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCB1—hematologic cancer	2.49e-06	3.68e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3R1—hematologic cancer	2.48e-06	3.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3R1—hematologic cancer	2.47e-06	3.66e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—hematologic cancer	2.47e-06	3.66e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	2.47e-06	3.65e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	2.46e-06	3.64e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—hematologic cancer	2.45e-06	3.62e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NQO1—hematologic cancer	2.43e-06	3.6e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CD44—hematologic cancer	2.43e-06	3.6e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	2.43e-06	3.59e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CASP3—hematologic cancer	2.42e-06	3.58e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—hematologic cancer	2.42e-06	3.58e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—hematologic cancer	2.42e-06	3.57e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NCOR1—hematologic cancer	2.42e-06	3.57e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.42e-06	3.57e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—hematologic cancer	2.41e-06	3.56e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JAK2—hematologic cancer	2.41e-06	3.56e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JAK2—hematologic cancer	2.4e-06	3.54e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—hematologic cancer	2.36e-06	3.49e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	2.36e-06	3.49e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—hematologic cancer	2.36e-06	3.48e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JUN—hematologic cancer	2.36e-06	3.48e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	2.35e-06	3.47e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MDM2—hematologic cancer	2.35e-06	3.47e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MDM2—hematologic cancer	2.34e-06	3.46e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CB—hematologic cancer	2.34e-06	3.45e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	2.31e-06	3.42e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	2.3e-06	3.41e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—hematologic cancer	2.3e-06	3.4e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYCS—hematologic cancer	2.3e-06	3.4e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.29e-06	3.38e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CB—hematologic cancer	2.29e-06	3.38e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	2.28e-06	3.38e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MTOR—hematologic cancer	2.28e-06	3.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1A—hematologic cancer	2.28e-06	3.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—hematologic cancer	2.28e-06	3.37e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	2.28e-06	3.37e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MTOR—hematologic cancer	2.28e-06	3.37e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.25e-06	3.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	2.24e-06	3.31e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	2.24e-06	3.31e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK8—hematologic cancer	2.23e-06	3.29e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—hematologic cancer	2.22e-06	3.29e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—hematologic cancer	2.18e-06	3.22e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	2.17e-06	3.21e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EP300—hematologic cancer	2.17e-06	3.21e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	2.14e-06	3.17e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	2.14e-06	3.16e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	2.14e-06	3.16e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MTHFR—hematologic cancer	2.14e-06	3.16e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CREBBP—hematologic cancer	2.14e-06	3.16e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	2.12e-06	3.13e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.12e-06	3.13e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	2.11e-06	3.12e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SRC—hematologic cancer	2.11e-06	3.12e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	2.1e-06	3.11e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CASP3—hematologic cancer	2.1e-06	3.11e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—hematologic cancer	2.1e-06	3.1e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CASP3—hematologic cancer	2.09e-06	3.1e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—hematologic cancer	2.09e-06	3.09e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—hematologic cancer	2.09e-06	3.09e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CREBBP—hematologic cancer	2.08e-06	3.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	2.08e-06	3.08e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—hematologic cancer	2.08e-06	3.08e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	2.06e-06	3.05e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—hematologic cancer	2.06e-06	3.04e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.06e-06	3.04e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	2.05e-06	3.03e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—hematologic cancer	2.05e-06	3.02e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JUN—hematologic cancer	2.04e-06	3.02e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—hematologic cancer	2.04e-06	3.01e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.04e-06	3.01e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JUN—hematologic cancer	2.03e-06	3.01e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.03e-06	3e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.03e-06	3e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CD—hematologic cancer	2.02e-06	2.99e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—hematologic cancer	2.02e-06	2.98e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	2.01e-06	2.97e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JUN—hematologic cancer	2e-06	2.96e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ALB—hematologic cancer	2e-06	2.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	1.98e-06	2.92e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—hematologic cancer	1.98e-06	2.92e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.98e-06	2.92e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—hematologic cancer	1.97e-06	2.92e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	1.97e-06	2.92e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—hematologic cancer	1.97e-06	2.91e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.96e-06	2.9e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALB—hematologic cancer	1.95e-06	2.88e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	1.95e-06	2.88e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	1.94e-06	2.87e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	1.94e-06	2.86e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK8—hematologic cancer	1.93e-06	2.85e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—hematologic cancer	1.93e-06	2.85e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	1.92e-06	2.85e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—EP300—hematologic cancer	1.92e-06	2.84e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.92e-06	2.84e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	1.92e-06	2.84e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.91e-06	2.83e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	1.89e-06	2.8e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—hematologic cancer	1.89e-06	2.8e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	1.89e-06	2.79e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	1.89e-06	2.79e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—EP300—hematologic cancer	1.88e-06	2.79e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EP300—hematologic cancer	1.88e-06	2.78e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.88e-06	2.78e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EP300—hematologic cancer	1.88e-06	2.77e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.87e-06	2.76e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.87e-06	2.76e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.87e-06	2.76e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.86e-06	2.75e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EP300—hematologic cancer	1.85e-06	2.73e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALB—hematologic cancer	1.84e-06	2.72e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SRC—hematologic cancer	1.83e-06	2.71e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SRC—hematologic cancer	1.82e-06	2.7e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SRC—hematologic cancer	1.8e-06	2.66e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.79e-06	2.65e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—hematologic cancer	1.78e-06	2.64e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	1.78e-06	2.63e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—hematologic cancer	1.77e-06	2.61e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.76e-06	2.61e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NRAS—hematologic cancer	1.76e-06	2.6e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—hematologic cancer	1.76e-06	2.6e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.76e-06	2.6e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NRAS—hematologic cancer	1.76e-06	2.6e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	1.75e-06	2.59e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—hematologic cancer	1.75e-06	2.59e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	1.73e-06	2.56e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	1.73e-06	2.55e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.72e-06	2.55e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—hematologic cancer	1.69e-06	2.49e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	1.68e-06	2.49e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.66e-06	2.46e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	1.66e-06	2.45e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.65e-06	2.44e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—hematologic cancer	1.64e-06	2.42e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFB1—hematologic cancer	1.64e-06	2.42e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—hematologic cancer	1.64e-06	2.42e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	1.63e-06	2.41e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.62e-06	2.4e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—hematologic cancer	1.61e-06	2.38e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	1.61e-06	2.38e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	1.61e-06	2.37e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.58e-06	2.33e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALB—hematologic cancer	1.56e-06	2.3e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—hematologic cancer	1.55e-06	2.3e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—hematologic cancer	1.52e-06	2.25e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—hematologic cancer	1.52e-06	2.24e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—hematologic cancer	1.51e-06	2.23e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.49e-06	2.2e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—hematologic cancer	1.49e-06	2.2e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	1.49e-06	2.2e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—hematologic cancer	1.49e-06	2.2e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—EP300—hematologic cancer	1.45e-06	2.15e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—hematologic cancer	1.42e-06	2.1e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.42e-06	2.1e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—EP300—hematologic cancer	1.42e-06	2.1e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—hematologic cancer	1.4e-06	2.07e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—hematologic cancer	1.39e-06	2.06e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	1.39e-06	2.06e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	1.39e-06	2.05e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.38e-06	2.05e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CB—hematologic cancer	1.38e-06	2.03e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.37e-06	2.02e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—hematologic cancer	1.35e-06	1.99e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—hematologic cancer	1.34e-06	1.99e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—EP300—hematologic cancer	1.34e-06	1.98e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.32e-06	1.95e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.31e-06	1.94e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—hematologic cancer	1.29e-06	1.9e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—hematologic cancer	1.28e-06	1.9e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.28e-06	1.9e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.26e-06	1.87e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—hematologic cancer	1.23e-06	1.82e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.23e-06	1.82e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.22e-06	1.8e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.21e-06	1.79e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALB—hematologic cancer	1.2e-06	1.78e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—hematologic cancer	1.19e-06	1.76e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—hematologic cancer	1.16e-06	1.72e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.15e-06	1.7e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—hematologic cancer	1.14e-06	1.68e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—hematologic cancer	1.14e-06	1.68e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.13e-06	1.68e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—EP300—hematologic cancer	1.13e-06	1.68e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.12e-06	1.65e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.08e-06	1.59e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.06e-06	1.57e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.05e-06	1.55e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—hematologic cancer	9.89e-07	1.46e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—hematologic cancer	9.17e-07	1.36e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—hematologic cancer	8.79e-07	1.3e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—EP300—hematologic cancer	8.75e-07	1.29e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—hematologic cancer	8.58e-07	1.27e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—hematologic cancer	8.38e-07	1.24e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—hematologic cancer	8.08e-07	1.19e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—hematologic cancer	6.85e-07	1.01e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.47e-07	9.56e-06	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—hematologic cancer	5.28e-07	7.81e-06	CbGpPWpGaD
